You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Type 2 Inflammation

AAAAI 2023 | Impact of Barrier Disruption and Type 2 Inflammation in Pediatric Patients With AD

Dr. Fred Ghali discusses the impact of type 2 inflammation and barrier disruption on pediatric patients with atopic dermatitis.

Fred Ghali
MD
Fred Ghali

Learning objectives

  • Examine interconnectivity between type 2 inflammation, barrier disruption, and clinical consequences of type 2 inflammatory diseases such as atopic dermatitis, asthma, and EoE
  • Understand onset and persistence of type 2 inflammation and potential disease trajectories of atopic dermatitis, asthma, and EoE in pediatric patients

Description

Join dermatologist Fred Ghali, MD, as he discusses the impact of type 2 inflammation and barrier disruption on pediatric patients with atopic dermatitis.

Tags
pediatricsymptomsquality of lifebarrier dysfunctionmicrobiome
MAT-GLB-2300884 v2.0 03/2023

About this expert

Dermatology

Fred Ghali

MD

Adjunct Associate Professor of Dermatology | University of Texas Southwestern Medical School and Baylor Medical Department of Dermatology, Dallas, United States

See author’s profile
Fred Ghali

Related resources

Type 2 Inflammation as the Common Thread in Multiple Diseases
Type 2 Inflammation
videoanimation

Type 2 Inflammation as the Common Thread in Multiple Diseases

EAACI 2023 | Pediatric Type 2 Inflammatory Disease Progression
Type 2 Inflammation
expert video

EAACI 2023 | Pediatric Type 2 Inflammatory Disease Progression

Type 2 Inflammatory Disease Trajectories: Unraveling Patterns of Disease Development and Burden in Pediatric Patients
Type 2 Inflammation
expert video

Type 2 Inflammatory Disease Trajectories: Unraveling Patterns of Disease Development and Burden in Pediatric Patients

Understanding the Pathophysiology of Pediatric Type 2 Inflammatory Diseases
Type 2 Inflammation
expert video

Understanding the Pathophysiology of Pediatric Type 2 Inflammatory Diseases

Genetics of Type 2 Inflammation
Type 2 Inflammation
expert video

Genetics of Type 2 Inflammation

Impact of Type 2 Inflammation on Pediatric Atopic Dermatitis, Asthma and Eosinophilic Esophagitis
Type 2 Inflammation
expert video

Impact of Type 2 Inflammation on Pediatric Atopic Dermatitis, Asthma and Eosinophilic Esophagitis

AAAAI 2023 | Pediatric Type 2 Inflammatory Disease Progression
Type 2 Inflammation
expert video

AAAAI 2023 | Pediatric Type 2 Inflammatory Disease Progression

AAAAI 2023 | Defining Type 2 Inflammation
Type 2 Inflammation
expert video

AAAAI 2023 | Defining Type 2 Inflammation

AAAAI 2023 | Impact of Barrier Disruption and Type 2 Inflammation in Pediatric Patients With AD
Type 2 Inflammation
expert video

AAAAI 2023 | Impact of Barrier Disruption and Type 2 Inflammation in Pediatric Patients With AD

AAAAI 2023 | How Type 2 Inflammation Can Contribute to the Progression of Asthma in Children
Type 2 Inflammation
expert video

AAAAI 2023 | How Type 2 Inflammation Can Contribute to the Progression of Asthma in Children

AAAAI 2023 | The Role of Type 2 Inflammation in EoE Disease Progression Throughout the Lifespan
Type 2 Inflammation
expert video

AAAAI 2023 | The Role of Type 2 Inflammation in EoE Disease Progression Throughout the Lifespan

Pruritic Dermatoses with a Type 2 Inflammation Component
Type 2 Inflammation
expert video

Pruritic Dermatoses with a Type 2 Inflammation Component

The Role of Type 2 Inflammation in the Pathophysiology of Atopic Dermatitis
Type 2 Inflammation
expert video

The Role of Type 2 Inflammation in the Pathophysiology of Atopic Dermatitis

What proportion of patients can achieve control in CRSwNP?
Type 2 Inflammation
expert video

What proportion of patients can achieve control in CRSwNP?

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?
Type 2 Inflammation
expert video

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?
Type 2 Inflammation
expert video

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?
Type 2 Inflammation
expert video

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

When is the right time to consider a biologic in patients with CRSwNP?
Type 2 Inflammation
expert video

When is the right time to consider a biologic in patients with CRSwNP?

How often do you suggest to assess sense of smell?
Type 2 Inflammation
expert video

How often do you suggest to assess sense of smell?

What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?
Type 2 Inflammation
expert video

What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?

Key Type 2 Cytokines Impact the Skin Microbiome in Atopic Dermatitis
Type 2 Inflammation
expert video

Key Type 2 Cytokines Impact the Skin Microbiome in Atopic Dermatitis

A Triad of Interacting Mechanisms Driving the Pathophysiology of AD, Asthma, CRSwNP, and EoE
Type 2 Inflammation
Infographic

A Triad of Interacting Mechanisms Driving the Pathophysiology of AD, Asthma, CRSwNP, and EoE

Explore the Global Burden of Pediatric AD (PEDISTAD)
Type 2 Inflammation
interactivity

Explore the Global Burden of Pediatric AD (PEDISTAD)

ADVENT On Air | Common Drivers of Type 2 Inflammatory Diseases
Type 2 Inflammation
Podcast

ADVENT On Air | Common Drivers of Type 2 Inflammatory Diseases

Type 2 Inflammation in AD Manifestations in Skin and Body
Type 2 Inflammation
expert video

Type 2 Inflammation in AD Manifestations in Skin and Body

Can early intervention modify the course of AD?
Type 2 Inflammation
expert video

Can early intervention modify the course of AD?

Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?
Type 2 Inflammation
expert video

Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?

Cumulative Exposure to Corticosteroids in Type 2 Inflammatory Diseases
Type 2 Inflammation
expert video

Cumulative Exposure to Corticosteroids in Type 2 Inflammatory Diseases

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone
Type 2 Inflammation
expert video

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone

Impact of Advanced Systemic Therapies on Disease Control in AD
Type 2 Inflammation
expert video

Impact of Advanced Systemic Therapies on Disease Control in AD

Partnering With Patients: Scores That Matter in CRSwNP
Type 2 Inflammation
Infographic

Partnering With Patients: Scores That Matter in CRSwNP

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AustraliaChange country/region